Before we get into our regular post let’s a take a moment to reflect on the news that Sanofi CEO Olivier Brandicourt had to get by last year on a mere $8.2 million. Per SEC filings and a post on the FirecePharma web site;
“Brandicourt’s total compensation actually fell in 2018, as the company suffered major sales declines in its flagship diabetes unit. The CEO’s pay package was slashed by 25% in 2018 to €7.28 million ($8.2 million), according to a new SEC filing.”
The post goes on:
“The problem was that the company . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.